ATE366570T1 - Verwendung von pentadiensäure-derivaten zur behandlung von hyperurikämie - Google Patents

Verwendung von pentadiensäure-derivaten zur behandlung von hyperurikämie

Info

Publication number
ATE366570T1
ATE366570T1 AT04797525T AT04797525T ATE366570T1 AT E366570 T1 ATE366570 T1 AT E366570T1 AT 04797525 T AT04797525 T AT 04797525T AT 04797525 T AT04797525 T AT 04797525T AT E366570 T1 ATE366570 T1 AT E366570T1
Authority
AT
Austria
Prior art keywords
acid derivatives
treat hyperuricemia
pentadienic acid
pentadienic
hyperuricemia
Prior art date
Application number
AT04797525T
Other languages
English (en)
Inventor
Robert Boizel
Pascale Fouqueray
Daniel Guerrier
Jean-Jaques Zeiller
Bertrand Brutzkus
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE366570T1 publication Critical patent/ATE366570T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
AT04797525T 2003-11-28 2004-11-02 Verwendung von pentadiensäure-derivaten zur behandlung von hyperurikämie ATE366570T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03292973A EP1535612B1 (de) 2003-11-28 2003-11-28 Behandlung von Hyperurikämie
US52777303P 2003-12-09 2003-12-09

Publications (1)

Publication Number Publication Date
ATE366570T1 true ATE366570T1 (de) 2007-08-15

Family

ID=34443102

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03292973T ATE339200T1 (de) 2003-11-28 2003-11-28 Behandlung von hyperurikämie
AT04797525T ATE366570T1 (de) 2003-11-28 2004-11-02 Verwendung von pentadiensäure-derivaten zur behandlung von hyperurikämie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03292973T ATE339200T1 (de) 2003-11-28 2003-11-28 Behandlung von hyperurikämie

Country Status (19)

Country Link
US (2) US20070099854A1 (de)
EP (2) EP1535612B1 (de)
JP (1) JP2007512267A (de)
KR (1) KR20060111541A (de)
CN (1) CN1886129A (de)
AR (1) AR046676A1 (de)
AT (2) ATE339200T1 (de)
AU (1) AU2004294686B2 (de)
BR (1) BRPI0417003A (de)
CA (1) CA2547543A1 (de)
CY (1) CY1105308T1 (de)
DE (2) DE60308390T2 (de)
DK (1) DK1535612T3 (de)
ES (2) ES2272926T3 (de)
PT (1) PT1535612E (de)
RU (1) RU2006122852A (de)
SI (1) SI1535612T1 (de)
WO (1) WO2005053676A1 (de)
ZA (1) ZA200605302B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7823417B2 (en) * 2005-11-04 2010-11-02 Ocv Intellectual Capital, Llc Method of manufacturing high performance glass fibers in a refractory lined melter and fiber formed thereby
CN103980267B (zh) * 2013-02-08 2018-02-06 镇江新元素医药科技有限公司 一类新型黄嘌呤氧化酶抑制剂的化合物及其药物组合物
WO2025021184A1 (zh) * 2023-07-27 2025-01-30 上海复宏汉霖生物医药有限公司 编码尿酸氧化酶的多核苷酸及其相关组合物和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787789B1 (fr) * 1998-12-29 2002-06-14 Lipha Benzopyranes et benzoxepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparations
WO2000047209A1 (en) * 1999-01-19 2000-08-17 Tularik Inc. Methods of modulating uric acid levels
PL357678A1 (en) * 2000-04-28 2004-07-26 Sankyo Company, Limited Ppargamma modulators
EP1389044A4 (de) * 2001-04-18 2006-07-05 Merck & Co Inc Ppar-alpha-gamma-liganden oder -agonisten für die behandlung von entzündungen
SE0101981D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors

Also Published As

Publication number Publication date
EP1686983A1 (de) 2006-08-09
EP1686983B1 (de) 2007-07-11
ES2286692T3 (es) 2007-12-01
ATE339200T1 (de) 2006-10-15
CY1105308T1 (el) 2010-03-03
JP2007512267A (ja) 2007-05-17
ES2272926T3 (es) 2007-05-01
ZA200605302B (en) 2007-04-25
US20100160410A1 (en) 2010-06-24
DE602004007546D1 (de) 2007-08-23
DE60308390T2 (de) 2007-09-06
CA2547543A1 (en) 2005-06-16
US20070099854A1 (en) 2007-05-03
RU2006122852A (ru) 2008-01-10
WO2005053676A1 (en) 2005-06-16
BRPI0417003A (pt) 2007-01-16
EP1535612A1 (de) 2005-06-01
KR20060111541A (ko) 2006-10-27
EP1535612B1 (de) 2006-09-13
CN1886129A (zh) 2006-12-27
PT1535612E (pt) 2006-12-29
AU2004294686A1 (en) 2005-06-16
DE60308390D1 (de) 2006-10-26
AU2004294686B2 (en) 2010-07-15
DK1535612T3 (da) 2007-02-12
SI1535612T1 (sl) 2006-12-31
AR046676A1 (es) 2005-12-14
DE602004007546T2 (de) 2008-01-31

Similar Documents

Publication Publication Date Title
ATE419856T1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE316077T1 (de) Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
ATE387194T1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE60234873D1 (de) Verwendung von COX-2 Inhibitoren zur Behandlung von affectiven Störungen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE438623T1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE602005027388D1 (de) Malonsäureamidderivate als inhibitoren von g-sekretase zur behandlung von alzheimer-krankheit
EP1924269A4 (de) Vegetationswasser-zusammensetzung zur behandlung von entzündlichen hautkrankheiten
ATE457725T1 (de) Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
ATE418337T1 (de) Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
ATE404203T1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
ATE366570T1 (de) Verwendung von pentadiensäure-derivaten zur behandlung von hyperurikämie
ATE376416T1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
ATE401878T1 (de) Verwendung von phenoxyessigsäurederivaten zur behandlung der hyperaktiven blase
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties